<DOC>
	<DOCNO>NCT00003195</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage cancer cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Interferon alfa may interfere growth cancer cell . PURPOSE : Phase II trial study effectiveness total-body irradiation , busulfan , interferon alfa follow peripheral stem cell bone marrow transplantation treat patient multiple myeloma .</brief_summary>
	<brief_title>Total-Body Irradiation , Busulfan , Interferon Alfa Followed Peripheral Stem Cell Bone Marrow Transplantation Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate effect total marrow irradiation busulfan follow allogeneic peripheral blood stem cell marrow transplantation outcome treatment related mortality , response , relapse , survival , event free survival patient advance multiple myeloma . OUTLINE : Peripheral blood stem cell ( PBSC ) bone marrow ( BM ) collection infusion perform accord standard practice . Patients undergo total marrow irradiation ( TMI ) bid 3 day . Busulfan administer every 6 hour day -6 -3 . PBSC BM infuse day 0 . Interferon alfa administer subcutaneously Mondays , Wednesdays , Fridays begin day 80 . Interferon therapy may continue absence graft versus host disease disease progression . Patients follow day 56 84 , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A maximum 30 patient accrue 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose stage II III multiple myeloma Stage I multiple myeloma progress conventional therapy HLA match donor Related age 1865 Unrelated age 1855 PATIENT CHARACTERISTICS : Age : 18 65 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No significant hepatic disease Bilirubin great 2 mg/dL Renal : Creatinine clearance least 40 mL/min Calcium great 15 mg/dL Cardiovascular : No significant cardiac disease Ejection fraction least 40 % Pulmonary : No significant pulmonary disease FEV1 least 50 % OR DLCO least 50 % Other : No obesity Chest wall great 3 cm thick No pendulous breast HIV negative PRIOR CONCURRENT THERAPY : Must receive prior conventional therapy stage I disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>